Novel Alphavirus Platforms for Chikungunya Diagnostics and Vaccination

Date: Friday, 02 05, 2016; Speaker: Scott Weaver, Ph.D., Director, Institute for Human Infections and Immunity, University of Texas Medical Branch ; Building: Building 50; First Floor Conference Rooms 1227/1233
Source: NIH Calendar of Events - Category: American Health Source Type: events

Related Links:

Aedes aegypti is a primary vector of dengue, chikungunya and Zika infections in India. In the absence of specific drugs or safe and effective vaccines for these infections, their control relies mainly on vector c...
Source: Parasites and Vectors - Category: Microbiology Authors: Tags: Research Source Type: research
Chikungunya virus (CHIKV) is an arthropod-borne virus (arbovirus) of epidemic concern, transmitted by Aedes ssp. mosquitoes, and is the etiologic agent of a febrile and incapacitating arthritogenic illness responsible for millions of human cases worldwide. After major outbreaks starting in 2004, CHIKV spread to subtropical areas and western hemisphere coming from sub-Saharan Africa, South East Asia, and the Indian subcontinent. Even though CHIKV disease is self-limiting and non-lethal, more than 30% of the infected individuals will develop chronic disease with persistent severe joint pain, tenosynovitis, and incapacitating...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Vector-Borne and Zoonotic Diseases, Ahead of Print.
Source: Vector-Borne and Zoonotic Diseases - Category: Infectious Diseases Authors: Source Type: research
Conditions:   Chikungunya;   Zika Interventions:   Biological: CHIK low dose;   Biological: CHIK mid dose;   Biological: CHIK high dose;   Biological: ZIKA low dose;   Biological: ZIKA mid dose;   Biological: ZIKA high dose;   Biological: Saline placebo Sponsor:   University of Oxford Not yet recruiting
Source: - Category: Research Source Type: clinical trials
On 15 April 2020, WHO received information regarding a confirmed case of yellow fever in Magandi village, Tchibanga city in Nyanga Province of southern Gabon, 590 km from the capital, Libreville. The case is an 83-year-old male with no known vaccination history for yellow fever. He had onset of symptoms on 30 January 2020 and presented to a health facility on 2 February 2020 with abdominal pain and jaundice. Between 2 February and 9 April, he consulted the Urban Health Centre in Tchibanga, the Christian Alliance Hospital in Bongolo and the University hospital in the capital Libreville where the case received anti-malarial ...
Source: WHO Disease Outbreaks - Category: Infectious Diseases Tags: news Source Type: news
n Chu Over the course of the last 50 years, the emergence of several arboviruses have resulted in countless outbreaks globally. With a high proportion of infections occurring in tropical and subtropical regions where arthropods tend to be abundant, Asia in particular is a region that is heavily affected by arboviral diseases caused by dengue, Japanese encephalitis, West Nile, Zika, and chikungunya viruses. Major gaps in protection against the most significant emerging arboviruses remains as there are currently no antivirals available, and vaccines are only available for some. A potential source of antiviral compounds c...
Source: Molecules - Category: Chemistry Authors: Tags: Review Source Type: research
AbstractChikungunya (CHIKV) reemerged in India after a gap of 32 years, in 2005 –2006 and has established endemicity in Pune. To assess the degree of CHIKV exposure, we estimated age-stratified prevalence of IgG antibodies to CHIKV in Pune population. This retrospective study utilized age-stratified serum samples collected from 15 wards of Pune in 2017 for dengue (DENV) virus study. Indirect anti-CHIKV-IgG ELISA was developed and used to test 1904 samples. Exposure to CHIKV and DENV was compared in the same population. CHIKV-specific plaque reduction neutralization test (PRNT) was employed to evaluate ELISA positivit...
Source: European Journal of Clinical Microbiology and Infectious Diseases - Category: Microbiology Source Type: research
In a statement, Bharat Bio said CEPI will fund the consortium for vaccine manufacturing and clinical development of a two-dose live-inactivated vaccine (BBV87) against Chikungunya.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
(International Vaccine Institute) CEPI, the Coalition for Epidemic Preparedness Innovations, in collaboration with Ind-CEPI, has announced a new partnering agreement with a consortium comprising Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) to advance the development of a Chikungunya vaccine. CEPI will provide the consortium with up to US $14.1 million for vaccine manufacturing and clinical development of a two-dose live-inactivated vaccine (BBV87) against Chikungunya.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
In conclusion, green synthesized nano-biomaterials can act as good antiviral agents. These nano-biomaterials can further be processed for formulation of effective and promising nanomedicines against CHIKV and other similar viruses which are a threat to human health. PMID: 32409081 [PubMed - in process]
Source: Appl Human Sci - Category: Physiology Authors: Tags: Mater Sci Eng C Mater Biol Appl Source Type: research
More News: American Health | Chikungunya | Conferences | Texas University | Vaccines